Agent with hematopoietic action

FIELD: pharmaceutical industry, in particular hematopoietic agent useful in treatment of iron-deficient anaemia.

SUBSTANCE: invention relates to application of extract from overground part of Pulmonaria mollissima with 10-30 % ethanol.

EFFECT: non-toxic agent with high hematopoietic action.

2 tbl, 2 dwg

 

The invention relates to biologically active total complexes of plant origin and can be used in clinical medicine as a hematopoietic agent in the treatment of iron deficiency anemia (IDA).

IDA is a disease of the blood system, caused by iron deficiency in the human body and accompanied by changes in its metabolism, decrease in hemoglobin in red blood cells, clinical manifestations anemic hypoxia. According to who, the IDA suffer every 3rd woman and every 6th man in the world.

An important factor is the high prevalence among the population of latent iron deficiency, which ranges from 19.5 to 30%. In addition, from 50 to 86% of women in different populations have risk factors for anemia. It should be noted that such a clinical syndrome of iron deficiency anemia as sideropenia and developed in subsequent fabric and Himicheskaya hypoxia lead to significant changes in the trophism of the skin and mucous membranes, disorders of the cardiovascular system (miocardio-dystrophy and circulatory varying degrees), nervous system (vegetative-vascular disorders, vestibular disorders, asthenic syndrome) and other organs and systems.

Iron deficiency can be linked to such health problems as decreased immunity, increased Veprik is ivoti to infections, reduced efficiency, complications of pregnancy and childbirth. The importance of rational and effective treatment of iron-deficiency anemia caused by frequency and medico-social value of this condition among the population, especially women of childbearing age, which most often occurs IDA.

Known means, containing iron in the form of its salts, such as phenols, sorbifer durules (Great Russian encyclopedia of medicines: 2 tons/ Sec. edit Ulescenko. - M.: Remedium, 2001). These drugs are quite effective in the treatment of iron deficiency anemia, however, ionic compounds of iron induce the emergence of free radicals. Created in the gastrointestinal tract of elevated concentrations of toxic ferraina lead to getting into mucosal cells, causing their death. Known cases of severe poisoning salt iron supplementation during prolonged application. This reduces therapeutic ability of these drugs.

It is also known hematopoietic tool - maltofer (Great Russian encyclopedia of medicines: 2 tons / Sec. edit Ulescenko. - M.: Remedium, 2001). In it the iron is in an insoluble form, in a colloidal solution. This complex (hydroxide-polymaltose complex iron) has a large molecular weight, which makes its diffusion through the membrane of cells is letisti membrane of the intestine, preventing their death. Absorption of iron in this case is fundamentally different scheme compared to ionic compounds of iron and is provided with intake of iron in the blood by active transport. The toxicity of the drug sharply reduced and, accordingly, reduces the incidence of side effects in the treatment of multiferon.

The above tools, solving the problem of the treatment of IDA, all are synthetic drugs that are alien to the human body.

Search and development of drugs from plant materials for the treatment of iron deficiency anemia due to the desire to develop an effective non-toxic blood-forming agent of plant origin.

The disclosure and implementation of inventions

The essence of the invention lies in the fact that as hematopoietic tools use product extraction (phytoextract) of lungwort softest Pulmonaria mollissima 10-30% ethanol.

List of figures illustrative material:

Figure 1. The dependence of the degree of extraction of extractive substances from the aerial parts Pulmonaria mollissima (in % of the mass of absolutely dry raw material) of ethanol concentration in the extractant.

Figure 2. Changes in the level of hemoglobin in rats with IDA without treatment and in the dynamics of treatment with a water-alcohol extract lungwort softest and mellifera.

The studies used elevated the art lungwort softest Pulmonaria mollissima A.Kemer family Boraginaceae (spread over), collected in the flowering stage and dried.

As extractant used purified water and an aqueous solution of ethanol. The choice of the concentration of ethanol was due to the completeness of extraction of extractive substances from plant material. Figure 1 shows the dependence of the mass of the extractive substances extracted from the aerial parts Pulmonaria mollissima (in % by weight of dry material) of ethanol concentration in the extractant. When using 10-30%ethanol content of extractives is 40±3% relative to the dry weight of the raw materials and does not change much.

Studies were performed on rats-females at two months of age weighing 175±15,

IDA caused in all rats by periodic (in a day) blood sampling from the tail vein in a volume of 2-3 ml IDA was diagnosed according to hemoglobin level (less than 50% of the physiological norm) and clinical manifestations (dry and pale skin, thinning and hair loss, brittle nails, sores around the nose and mouth).

To achieve IDA rats randomly divided into the following 4 groups of 6 animals each:

- control group (animals not treated),

the comparison group 1 (animals treated with mellifera),

the comparison group 2 (animals treated water extract lungwort softest),

- experienced group of animals was treated with a water-alcohol extract lungwort magkaisa is according to the invention).

Most often used in herbal medicine daily dose is the dose phytoextract obtained by extracting from the crushed dry raw herbaceous medicinal plants volume 1 table spoon of that lungwort softest is 5, This dose was taken as the basis for the calculation of therapeutic dose of phyto-extracts from lungwort softest.

Preparations (aqueous and aqueous-alcoholic) received twice by extraction of dried and crushed material lungwort softest. Previously it was found that the amount of extractives removed during the two - and three-fold extraction, is almost the same.

Obtaining an aqueous extract of lungwort softest

5 g of dry raw material was filled with purified water in a volume of 200 ml of the Extraction was performed for 30 minutes in a boiling water bath. The resulting broth was filtered. The remainder of the raw material was re-filled with water in a volume of 200 ml, the extraction was performed for 30 minutes in a boiling water bath, the broth was filtered. Obtained after the first and second extraction of broths were combined and liofilizirovanny at a temperature of 30-50°C. the Yield of dry extract of about 2.5,

Obtaining water-alcohol extract lungwort softest

5 g of dry raw material is filled in 20% ethanol in a volume of 200 ml of the Extraction was performed for 30 minutes in a boiling water bath. As what was said. The remainder of the raw material was re-filled with 20%aqueous solution of ethanol in a volume of 200 ml was kept for 30 minutes in a boiling water bath, aqueous-alcoholic extract (water-alcohol extract) was filtered. Broths obtained after the first and second extractions were combined and liofilizirovanny at a temperature of 30-50°C. the Yield of dry extract is about 2,

The calculation of therapeutic dose of aqueous and hydro-alcoholic extracts

Doses for injection was calculated as the iron content in the extract.

The iron content in the dry raw materials lungwort is to 31.1 mg %. For the preliminary experiments data from dry raw material lungwort softest in aqueous and aqueous-alcoholic extract (10-30% ethanol) and the above conditions of extraction goes 50% of iron.

Thus, the broth (and then dry extract)obtained from the original 5 g dry raw material contains 0.8 mg of iron (the amount of iron contained 2.5 g of dry aqueous extract or 2 g of dry water-alcohol extract).

The dose of 0.8 mg of iron may be taken as a daily dose for a person with average weight (70 kg), which in terms of 1 kg of weight amounting to 11.5 mg/kg Daily dose (iron) for rats weighing 0,175 kg is 2 g. The specified amount of iron contained 5 mg of the dry hydro-alcoholic extract or 6.25 mg of dry water extras the KTA.

The calculation of the dose of maltofer (drops)

The recommended dose of maltofer for the treatment of clinically significant iron deficiency are for children 12 years and older : 40-120 drops per day (on average 80 drops/day), in the calculation of average weight (70 kg) is 1,14 drops/kg per day [(1 ml (20 drops) of maltofer contains 176,5 mg iron-hydroxide polymaltose complex (50 mg elemental iron); 1 drop contains 2.5 mg of elemental iron)]. For rats weighing 0,175 kg daily dose of maltofer will be 0.2 drops/day. This dose of maltofer contains 500 mcg of elemental iron.

Before the introduction of the above dry extracts (dose calculated on the individual weight of the rat) was dissolved in 1 ml of warmed up to 37°purified water, maltofer in droplets (in the individual dose for each rat) brought up to a volume of 1 ml by adding purified water. All of the preparations was carried out orally through a feeding tube before feeding the animals daily for 10 days. In the treatment periodically made determining the level of hemoglobin in the blood.

From the obtained data (table 1), it follows that the level of hemoglobin in rats without treatment normalized to the 20-th day, while groups with treatment hemoglobin level is normalized to the 10-th day, i.e. in 2 times faster.

tr>
Table 1.

The level of hemoglobin in animals with IDA on the 5th and the 10th day of the treatment
The group of animalsThe level of hemoglobin (X±m) P<0,05; g/l
Day 510th dayDay 20
the control group79,2±3,498,0±9,5151±4,5
group treatment mellifera126,6± and 11.3155,8±4,4-
group treatment by an aqueous extract88,9±4,2119,2±6,1-
group treatment with a water-alcohol extract112,8±6,5154, 6mm±6,4-

The dependence of the level of hemoglobin from time to time in rats without treatment is linear, and the dependence of hemoglobin level on the duration of treatment mellifera and water-alcohol extract lungwort softest have two plots (figure 2):

- linear plot in the first interval of 7 days, at which the rate of increase of hemoglobin is to 10.9 g/l per day, which is almost 3 times higher than in the control group (3,9 g/l / day);

- plot of saturation, where the growth rate of hemoglobin dramatically slowed.

The nature of changes in hemoglobin level with the introduction of m is Lopera and extract lungwort such, indicating a similar mechanism of pharmacological action of both drugs.

Normalization of hemoglobin level in rats treated with the extract obtained by using as the extractant water to the 10-th day has not been achieved, indicating that it has lower efficacy in the treatment of iron deficiency anemia than those of the proposed tools.

The study suggested the drug lungwort softest on acute toxicity

To determine the safety of the proposed drug were testing for acute toxicity according to the standard technique (see State Pharmacopoeia XI edition, issue 2, str). Aqueous-alcoholic extract was administered to mice once in doses of 5000 and 10000 mg/kg of body weight. When observed within 14 days of the experimental mice was not observed changes in behavioral reactions, diarrhea signs, any other toxic pathophysiological manifestations. The death of animals is not reached. Therefore, the investigated aqueous-alcoholic extract lungwort softest according to GOST 12.1.007-76 can be attributed to the 4th class of "low hazard substances" value LD50>10000 mg/kg

Table 2 shows comparative data on the safety of the drug lungwort and synthetic iron preparations (see Sobolev M.K. Iron deficiency anemia in young children: diagnosis and modern treatment / M.K is obolev // Issues of Hematology, Oncology and immunology. - 2003. - Vol.2, No. 2. - p.32-37), from which we can conclude that a significantly higher security applications, the total extract of the aerial parts of the lungwort softest compared with multiferon.

Table 2.

The toxicity of different iron preparations
MedicationAcute toxicity (LD50for different preparations of iron, mg/kg
Iron sulfate (phenyls)230
Maltofer2000
Aqueous-alcoholic extract lungwort softest>10000

With pharmacoeconomic position, the application of aqueous-alcoholic extract of the aerial parts of the lungwort softest, of course, also has advantages over the expensive import drug maltofer.

From the obtained experimental data follows:

1. A hydroalcoholic extract of the aerial parts of the lungwort softest it has expressed the hematopoietic effect;

2. The inventive product has no toxicity and is not vulnerable to the harmful actions;

3. The tool can be recommended in clinical therapy of iron deficiency anemia.

4. The inventive tool is significantly less toxic than those used for the treatment of W Is And drugs such as iron sulfate (phenols) and maltofer.

5. The effectiveness of aqueous-alcoholic extract lungwort close to the performance of maltofer and therapeutic dose of aqueous-alcoholic extract lungwort (iron) 250 times less than the dose of maltofer.

6. Aqueous-alcoholic extract lungwort softest is more efficient blood-forming agent as compared with the aqueous extract lungwort softest.

A means of having hematopoietic activity, characterized in that it is a product extracted from the aerial parts of the lungwort softest Pulmonaria mollissima 10-30%ethanol.



 

Same patents:

FIELD: organic chemistry, chemical technology, medicine, pharmacy.

SUBSTANCE: invention relates to novel synthetic 2-(α-hydroxypentyl)benzoates of the general formula (I): wherein M means a monovalent metal ion, bivalent metal ion or a basic organic group chosen from a aniline group, benzylamino-group, morpholinyl group or diethylamino-group and wherein n = 1 or 2. Also, invention relates to methods for synthesis of these compounds and pharmaceutical compositions containing these salts as active components. Also, invention relates to using abovementioned compounds in prophylaxis and treatment of heart ischemia, brain ischemia, occlusion of heart and brain arteries.

EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions.

14 cl, 3 tbl, 20 ex

FIELD: medicine, hematology, polypeptides.

SUBSTANCE: invention discloses compositions comprising factor VII or polypeptide relates to factor VII, and PAI-1 or PAI-1-related polypeptide, and for using this composition in treatment of bleeding. Invention discloses a method for treatment of bleeding in a patient, a method for decreasing the coagulation time in a patient, a method for enhancing hemostasis in a patient, a method for increasing the fibrinolysis time in a patient, a method for enhancing clots strength in a subject, a set designated for treatment of bleeding attack. Invention provides the development of compositions that can be used effectively in treatment or prophylaxis of bleeding in blood coagulation disorders, in particularly, the development of compositions as a single, standard medicinal formulation that can be used effectively in treatment or prophylaxis of bleeding or as a procoagulant, the development of compositions, methods for treatment and sets using of that promotes to displaying the synergetic effect, the development of compositions, methods for treatment and sets without essential adverse effects, for example, high level of systemic activation of the blood coagulation system.

EFFECT: improved and valuable medicinal properties of polypeptides and pharmaceutical composition.

53 cl, 4 dwg

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to haemostatic glue powder. Proposed powder represents a mixture containing sodium alginate and feracryl taken in the weight ratio = 1:(1-3). Using a powder provides ceasing bleeding and after contacting with blood and tissues it forms a film for about 10-30 s. Also, powder doesn't stick to hands.

EFFECT: improved and valuable medicinal properties of powder.

6 ex

FIELD: medicine.

SUBSTANCE: method involves applying superbranched amylopectin or its derivative like hydroxyethylamylopectin possessing moderate branching degree expressed in anhydroglucose mole % of carrying bifurcation point being not greater than 10-25 mole % large and weighted average mass MM belonging to interval of 40000-800000 D. The amylopectin is applied in surgical and therapeutical methods for treating people or animals or in diagnostic purposes. The volume plasma-substitutes based on hydroxyethylated amylopectin have disadvantages occurred to present time as a result of hydroxyethylation application like incomplete metabolism and therefore accumulation in tissues with time that is related to adverse side effects. New plasma-substitutes based on polisaccharides are shown.

EFFECT: enhanced effectiveness of treatment; controlled dissociation under serum α-amylase.

7 cl

FIELD: medicine, pharmacy, pharmaceutical technology.

SUBSTANCE: invention describes a medicinal formulation possessing an anti-aggregating effect. Proposed medicinal formulation consists of a core comprising the following components, wt.-%: clopidogrel hydrosulfate, 44.0-65.0; lactose, 15.0-37.0; starch, 2.4-9.8; microcrystalline cellulose, 2.2-7.0; hydroxypropylmethylcellulose, 0.3-0.8; polyethylene glycol, 1.5-4.0; magnesium stearate, 0.1-1.0, and stearic acid, 0.1-1.0, and envelope comprising the following components, wt.-%: hydroxypropylmethylcellulose, 58.0-72.0; polyethylene glycol, 13.5-20.5; titanium dioxide, 13.5-20.5, and red iron oxide, 0.5-1.0. Also, invention discloses a method for preparing this medicinal formulation. Hydroxypropylmethylcellulose as a component of a core enhances mechanical strength of tablet that provides optimization of the envelope applying process. Additional technological procedure in preparing a mixture of potato starch with polyethylene glycol 6000 Da and part of clopidogrel hydrosulfate allows uniform distribution of components that enhanced bioavailability of the medicinal agent and increased anti-aggregation effect of the preparation being without elevating the therapeutic dose Invention can be used in prophylaxis of ischemic disturbance in patients suffering from atherosclerosis.

EFFECT: improved preparing method, valuable medicinal properties of formulation.

6 cl, 1 tbl, 3 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to novel compounds of the formula (I) and their pharmaceutically acceptable salts and/or pharmaceutically acceptable esters. Proposed compounds possess properties of agonists of receptors activated by peroxisome proliferators (PPAR agonists) and can be used in treatment of such diseases as diabetes mellitus, hypertension, atherosclerotic diseases and others. In the general formula (I) R1 represents phenyl, optionally mono-, di- or tri-substituted with halogen atom, lower alkyl, fluorine-lower alkyl, lower alkoxy-group; R2 represents hydrogen atom or lower alkyl; R3 and R4 represents independently of one another hydrogen atom, hydroxy-group, halogen atom, lower alkyl, fluorine-(lower alkyl), lower alkoxy-group wherein at least one of radicals R3 and R4 doesn't represent hydrogen atom; R5 represents lower alkoxy-group; R6 represents hydrogen atom or lower alkyl; n = 1. Also, invention relates to a pharmaceutical composition based on compounds of the invention.

EFFECT: valuable medicinal properties of compounds.

19 cl, 1 tbl, 7 sch, 56 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention describes water-soluble iron-carbohydrate complexes containing 10-40 wt.-% of iron. Complexes can be prepared from ferric (III) salt aqueous solution and oxidation product aqueous solution of one or more maltodextrins with hypochlorite aqueous solution at alkaline pH value. In using one maltodextrin its dextrose equivalent is from 5 to 20, and in using mixture of maltodextrins the dextrose equivalent is from 5 to 20 and dextrose equivalent of each maltodextrin as component of mixture is from 2 to 40. Also, invention describes a method for preparing this complex and medicinal agents used in treatment and prophylaxis of states associated with iron deficiency.

EFFECT: improved preparing method, valuable medicinal properties of complexes.

15 cl, 1 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: invention proposes using recombinant protein with the molecular mass 12 kDa from leech, Hirudo medicinalis, (saratin) that inhibits vWF-dependent formation of bond of platelets with artery wall collagen under condition of enhanced shift. Proposed agent is used for inhibiting platelets accumulation after vessel damage or endarterectomy for prevention of adhesion of platelets, thrombosis and restenosis. Also, invention proposes a coat for surface of surgery device or surgery tool based on thereof, hydrogel coat of catheter for administration and local delivery of saratin and using saratin as an agent for coat of surgery device or surgery tool, i. e. catheter, stent or intravascular transplant. Invention displays decreasing rate in thrombosis development and vessels occlusion in point of impact being in the absence of systemic effects as saratin doesn't influence on systemic bleeding and amount of platelets.

EFFECT: valuable medicinal properties of agent.

10 cl, 3 tbl, 9 dwg, 12 ex

FIELD: synthesis of biologically active compounds.

SUBSTANCE: invention provides novel condensed furan compounds of general formula I: , wherein circle X represents benzene, pyridine, or the like; Y optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted piperidyl, oxo-substituted pyrrolydyl, or oxo-substituted morpholino group; R3 hydrogen and the like; and R4 is hydrogen, or a pharmaceutically acceptable salt thereof, which are useful as drugs, especially as inhibitor of activated blood coagulation factor A, as well as intermediate compounds.

EFFECT: expanded synthetic possibilities in furan series and increased choice of biologically active compounds.

16 cl, 85 tbl, 481 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with creating anticoagulant preparations of animal origin, moreover, it deals with the one being a fragment of collagen at molecular weight of about 12 kDa containing about 10.0-12.0% carbohydrates, 6.0-7.5% sulfate groups, macro- and microelements. The method for obtaining this preparation deals with homogenization, extracting with distilled water at pH being 8.0-8.5 followed by treating the extract with enzymatic preparation at about 35-37°C at pH being 7.5-8.5 for 3.5-4.5 h, then it is necessary to add ethanol to the mixture cooled up to room temperature up to its content in the extract of 40% and then the developed filamentous residue should be separate, protein fibers should be pressed upon a filter and successively washed with 40%- and 96%-ethanol and dried, then the product should be dissolved in 0.05-0.1 M sodium bicarbonate solution, then one should repeat fermentolysis under the same conditions; the solution obtained should be supplemented with ethanol up to its final concentration of 50%; the residue should be pressed upon a cloth filter, washed with 50%-ethyl alcohol solution in distilled water, and then - with 96%-ethyl alcohol to be dried on air; then the product should be dissolved in water and deposited with acid, the residue should be separated due to centrifuging, dissolved in sodium bicarbonate, then protein-containing solution should undergo dialysis or ultrafiltration upon a membrane being permeable for substances at molecular weight being 15 kDa, after that desalinized protein solution should be separated by passing it through a sterilizing membrane at pore size of 0.2 mcm, then membrane-passing protein fraction should be collected and the target product should be dried. The innovation widens the range of substances of another mechanism of anticoagulant action against the action of heparin and, also, decreases the quantity of side effects and extends raw material basis for obtaining preparations of anticoagulant activity.

EFFECT: higher efficiency.

3 cl, 6 dwg, 7 ex, 2 tbl

FIELD: veterinary.

SUBSTANCE: claimed stimulator contains alcohol extract obtain from mixture of ground Echinacea purpurea, foalfoot grass and inflorenscences, creeping thyme grass, and liquorice roots in equal amounts with 70 % alcohol in ratio of 1:10. Mixture is conditioned in dark room at 15-20°C followed by straining with simultaneous raw material squeezing, and filtering. Claimed method includes intramuscularly injection of nonspecific immunoglobuline, orally administration of said biologically active stimulator in form of 7-8 % aqueous solution in dose of 2.0-2.5 ml/kg of animal mass for 10-15 days with 24 h interval.

EFFECT: agent of high healthy effect, enhanced assortment of immunostimulating agent.

2 cl, 4 ex, 5 tbl

FIELD: veterinary.

SUBSTANCE: claimed stimulator contains alcohol extract obtain from mixture of ground Echinacea purpurea, foalfoot grass and inflorenscences, creeping thyme grass, and liquorice roots in equal amounts with 70 % alcohol in ratio of 1:10. Mixture is conditioned in dark room at 15-20°C followed by straining with simultaneous raw material squeezing, and filtering. Claimed method includes intramuscularly injection of nonspecific immunoglobuline, orally administration of said biologically active stimulator in form of 7-8 % aqueous solution in dose of 2.0-2.5 ml/kg of animal mass for 10-15 days with 24 h interval.

EFFECT: agent of high healthy effect, enhanced assortment of immunostimulating agent.

2 cl, 4 ex, 5 tbl

FIELD: veterinary.

SUBSTANCE: claimed stimulator contains alcohol extract obtain from mixture of ground Echinacea purpurea, foalfoot grass and inflorenscences, creeping thyme grass, and liquorice roots in equal amounts with 70 % alcohol in ratio of 1:10. Mixture is conditioned in dark room at 15-20°C followed by straining with simultaneous raw material squeezing, and filtering. Claimed method includes intramuscularly injection of nonspecific immunoglobuline, orally administration of said biologically active stimulator in form of 7-8 % aqueous solution in dose of 2.0-2.5 ml/kg of animal mass for 10-15 days with 24 h interval.

EFFECT: agent of high healthy effect, enhanced assortment of immunostimulating agent.

2 cl, 4 ex, 5 tbl

FIELD: wood-working and wood chemical industry.

SUBSTANCE: proposed method of birch bark processing includes crushing birch bark in crusher; separation into silver bark and bast: extraction of silver bark using solvent in form of zeotropic mixture of tetrachloroethylene and water; separation of solution from cake; separation of precipitated crystals from mother liquor, washing of crystals with subsequent drying of received product - mixture of three-five triterpene compounds; boiling down of mother liquor to get dry remnant, washing the latter in distilled water with subsequent drying of obtained product - mixture of five-seventeen triterpene compounds; removal of solvent from said cake by mixing it with water and subsequent boiling down of mixture for complete removal of solvent; mixing of said cake with sodium hydroxide and isopropyl alcohol, boiling of said mixture, separation of solution from undissolved sidement, washing of undissolved sediment with distilled water and subsequent drying of obtained product - ligning; distillation of isopropyl alcohol from filtrate, acidification of remaining solution to pH=4.5 - 5.5 and holding it at temperature from minus 5 to 25°C for 0.5-15 h. separation of precipitated sediment from solution, washing of sediment with subsequent drying of obtained product - birch wax; crushing of bast, mixing of bast particles with water, holding of mixture for 1-20 days, separation of sediment from obtained product - sour compound; drying of sediment which can be used as feed additive for cattle and poultry.

EFFECT: provision of complex processing of birch bark.

24 cl, 3 ex, 2 dwg

Biocidal gel // 2305544

FIELD: pharmaceutical industry, in particular biocide agent.

SUBSTANCE: claimed gel includes hydroxyethyl cellulose, polyguanidine compound (e.g. polyhexamethylene guanidine succinate or poly-(4,9-dioxadodecan guanidine) succinate), glycerol, trilon B, polyethylene glycol, citric acid, perfume composition, and water. Additionally it contains neonol, calcium pantothenate and chamomile extract in specific component ratio.

EFFECT: gel with increased biocidal action.

3 tbl, 3 ex

Biocidal gel // 2305544

FIELD: pharmaceutical industry, in particular biocide agent.

SUBSTANCE: claimed gel includes hydroxyethyl cellulose, polyguanidine compound (e.g. polyhexamethylene guanidine succinate or poly-(4,9-dioxadodecan guanidine) succinate), glycerol, trilon B, polyethylene glycol, citric acid, perfume composition, and water. Additionally it contains neonol, calcium pantothenate and chamomile extract in specific component ratio.

EFFECT: gel with increased biocidal action.

3 tbl, 3 ex

Biocidal gel // 2305544

FIELD: pharmaceutical industry, in particular biocide agent.

SUBSTANCE: claimed gel includes hydroxyethyl cellulose, polyguanidine compound (e.g. polyhexamethylene guanidine succinate or poly-(4,9-dioxadodecan guanidine) succinate), glycerol, trilon B, polyethylene glycol, citric acid, perfume composition, and water. Additionally it contains neonol, calcium pantothenate and chamomile extract in specific component ratio.

EFFECT: gel with increased biocidal action.

3 tbl, 3 ex

FIELD: cosmetic medicine.

SUBSTANCE: invention proposes a method for reducing growth of human hair by way of applying dermatologically acceptable topical-administration composition onto skin in amount sufficient to reduce hair growth, which composition contains α-difluoromethylornitin (DFMO) and dermatologically acceptable carrier including at least 4% polyoxyethylene ether to provide percutaneous effects.

EFFECT: enhanced percutaneous power of active ingredient (DFMO).

38 cl, 2 tbl, 6 ex

FIELD: cosmetic products.

SUBSTANCE: invention relates to antiperspirant compositions for human skin application methods for production and uses thereof. Transparent anhydrous antiperspirant compositions contain from 1 to 30 mass % of quick antiperspirant salt dispersed in water immiscible liquid carrier, which is cured with effective amount of structuring agent.

EFFECT: compositions with improved transparency.

32 cl, 4 ex, 5 tbl

FIELD: cosmetic products.

SUBSTANCE: invention relates to antiperspirant compositions for human skin application methods for production and uses thereof. Transparent anhydrous antiperspirant compositions contain from 1 to 30 mass % of quick antiperspirant salt dispersed in water immiscible liquid carrier, which is cured with effective amount of structuring agent.

EFFECT: compositions with improved transparency.

32 cl, 4 ex, 5 tbl

FIELD: medicine, oncology, amino acids.

SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.

EFFECT: valuable medicinal antitumor properties of preparation.

8 cl, 4 tbl, 2 dwg, 4 ex

Up!